Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease - Scorecard - MDSpire

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • By

  • Vasantharaja Raguraman

  • Miranda Mysinger

  • Mohit Verma

  • Shanid Mohiyuddin

  • Nashwan Jabbour

  • Melissa Kesler

  • Trupti Joshi

  • Senthilnathan Palaniyandi

  • Gerhard C. Hildebrandt

  • June 11, 2026

  • 0 min

Share

Clinical Scorecard: Inhibition of Bruton Tyrosine Kinase by Acalabrutinib Reduces Chronic Graft-Versus-Host Disease in Murine Models of Scleroderma

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingPreclinical murine models.

Key Highlights

  • Add specific survival rates and clinical score improvements.

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider BTK inhibitors like acalabrutinib for treatment of cGVHD.
    • Explore additional management strategies for cGVHD.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • monitoring

        Related Resources & Content

        Original Source(s)

        Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

        • by Vasantharaja Raguraman, Miranda Mysinger, Mohit Verma, Shanid Mohiyuddin, Nashwan Jabbour, Melissa Kesler, Trupti Joshi, Senthilnathan Palaniyandi, Gerhard C. Hildebrandt

        • June 11, 2026

        Related Content

        Editorial: Gene regulation in lymphocyte development and response

        Association of achieved LDL-C levels with global coagulability and clinical outcomes in patients with acute coronary syndrome receiving PCSK9 inhibitors: a prospective cohort study

        Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis